JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

Search

CareDx Inc

Cerrado

SectorSanidad

20.1 3.88

Resumen

Variación precio

24h

Actual

Mínimo

19.01

Máximo

20.33

Métricas clave

By Trading Economics

Ingresos

10M

1.7M

Ventas

13M

100M

P/B

Media del Sector

15.953

84.243

Margen de beneficios

1.674

Empleados

644

EBITDA

11M

6.8M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

-7.55% downside

Dividendos

By Dow Jones

Próximas Ganancias

25 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

301M

1.1B

Apertura anterior

16.22

Cierre anterior

20.1

Noticias sobre sentimiento de mercado

By Acuity

80%

20%

325 / 352 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

CareDx Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

9 feb 2026, 17:25 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

9 feb 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

9 feb 2026, 23:43 UTC

Charlas de Mercado

Gold Falls on Possible Technical Correction -- Market Talk

9 feb 2026, 23:14 UTC

Charlas de Mercado

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

9 feb 2026, 22:29 UTC

Charlas de Mercado

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

9 feb 2026, 22:19 UTC

Charlas de Mercado

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

9 feb 2026, 22:08 UTC

Charlas de Mercado

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

9 feb 2026, 22:01 UTC

Ganancias

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

9 feb 2026, 21:59 UTC

Ganancias

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

9 feb 2026, 21:59 UTC

Ganancias

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

9 feb 2026, 21:58 UTC

Ganancias

Friedman Industries 3Q Sales $168M >FRD

9 feb 2026, 21:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

9 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 feb 2026, 21:48 UTC

Ganancias

Friedman Industries 3Q EPS 43c >FRD

9 feb 2026, 21:17 UTC

Ganancias

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

9 feb 2026, 21:13 UTC

Charlas de Mercado

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

9 feb 2026, 21:04 UTC

Ganancias

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

9 feb 2026, 20:30 UTC

Charlas de Mercado

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

9 feb 2026, 20:02 UTC

Charlas de Mercado

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

9 feb 2026, 19:42 UTC

Charlas de Mercado

Japan's Yield Curve Expected to Flatten -- Market Talk

9 feb 2026, 19:31 UTC

Charlas de Mercado

Nike Seen Regaining Relevance With Consumers -- Market Talk

9 feb 2026, 19:27 UTC

Charlas de Mercado

Gold Climbs Back Over $5,000/oz -- Market Talk

9 feb 2026, 19:05 UTC

Charlas de Mercado

Nike Returns to List of Hottest Brands -- Market Talk

9 feb 2026, 18:19 UTC

Charlas de Mercado

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

9 feb 2026, 17:41 UTC

Ganancias
Adquisiciones, fusiones, absorciones

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

9 feb 2026, 17:31 UTC

Ganancias
Adquisiciones, fusiones, absorciones

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

9 feb 2026, 17:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

9 feb 2026, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 feb 2026, 17:17 UTC

Charlas de Mercado

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

9 feb 2026, 17:16 UTC

Ganancias

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Comparación entre iguales

Cambio de precio

CareDx Inc previsión

Precio Objetivo

By TipRanks

-7.55% descenso

Estimación a 12 Meses

Media 18 USD  -7.55%

Máximo 18 USD

Mínimo 18 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CareDx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

4 ratings

0

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

14.77 / 18.49Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

325 / 352 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat